Brazil's Biolab to produce Roche flu drug Xofluza under UN-backed license

The Medicines Patent Pool selected Brazil's Biolab to manufacture and sell Roche's antiviral baloxavir marboxil (Xofluza) in Brazil, under a voluntary licensing agreement announced at a UN General Assembly side event. This expands access to a novel flu treatment in a middle-income country, though volume and pricing terms remain undisclosed. The move signals continued efforts to bolster pandemic preparedness through voluntary licensing.